Podcasts about tavr

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Chris Malaisrie, a Professor of Surgery in the Division of Cardiac Surgery at Northwestern University and an Attending Cardiac Surgeon at Northwestern Medicine, about valve-sparing aortic root replacement techniques. Chapters 00:00 Intro 02:25 TAVR Heart Team Coverage 03:52 JANS 1, TAVR vs SAVR Perspective 10:50 JANS 2, Gene-Edited Transplant Model 13:13 JANS 3, Long-Term Outcomes Atrial Fib 14:31 JANS 4, 147-Minute Drowning Circ Arrest 18:01 Video 1, Double Ann Enlargement Prosth Mis 20:48 Video 2, Reop Aortic Root Reconstruction 22:24 Video 3, Normothermic AA Aneurysm 24:22 Dr. Malaisrie, Aortic Root Replacement 41:42 Closing The conversation covers a wide range of procedures, including the Bentall, Yacoub, and David operations, as well as the Ross procedure and personalized external aortic root support (PEARS). They further explore approaches to mitral and aortic valve repair, the management of diseased leaky valves, and the advantages of the Stanford modification of the David V procedure. Dr. Malaisrie concludes the discussion by offering advice to surgeons on refining their valve repair skills and shares his prediction for the future of valve repair surgery. Joel also highlights recent JANS articles on age vs lifetime perspective on the transcatheter vs surgical aortic valve implantation, gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants, long-term outcomes of postoperative atrial fibrillation after cardiac surgery, and a case on ice water drowning survival after 147-minute submersion and 7 °C hypothermic circulatory arrest. In addition, Joel explores double annular enlargement as an effective technique to overcome patient-prosthesis mismatch, reoperation for aortic root reconstruction, and normothermic treatment of an aortic arch aneurysm. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned Transcatheter vs Surgical Aortic Valve Implantation: Age vs Lifetime Perspective Gene-Edited Pig Cardiac Xenotransplantation as a Bridge to Allotransplantation in Infants: Progress in a Pig-to-Baboon Model Long-Term Outcomes of Postoperative Atrial Fibrillation After Cardiac Surgery: Results From 19,000 Patients Ice Water Drowning Survival After 147-Minute Submersion and 7 °C Hypothermic Circulatory Arrest CTSNet Content Mentioned Double Annular Enlargement as an Effective Technique to Overcome Patient-Prosthesis Mismatch Reoperation for Aortic Root Reconstruction Normothermic Treatment of an Aortic Arch Aneurysm Other Items Mentioned Centers for Medicare & Medicaid Services Database—TAVR Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826261450851

CardioNerds co-chairs Dr. Dinu Balanescu and Dr. Billy Joe Mullinax, along with FIT lead Dr. Shiavax Rao, discuss the evolving landscape of randomized controlled trials in pulmonary embolism with Dr. Jay Giri, interventional cardiologist, Associate Professor of Medicine, and Director of the Cardiovascular Catheterization Laboratories at the Hospital of the University of Pennsylvania. This episode examines the historical evidence behind systemic thrombolysis, the emergence of catheter-directed therapies and mechanical thrombectomy, and the landmark RCTs – STORM-PE, PEERLESS, HI-PEITHO, and PEERLESS II – that are reshaping intermediate-risk PE management. The discussion highlights challenges in PE trial design, the critical importance of clinical deterioration as an endpoint, and why this era represents an unprecedented wave of evidence generation in PE. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Dr. Dinu Balanescu and Dr. Billy-Joe Mullinax are Co-chairs for the CardioNerds PE Series, developed in collaboration with the PERT Consortium.   Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls: Systemic thrombolysis in intermediate-risk PE reduces hemodynamic decompensation but at the cost of ~1.5–2% intracranial hemorrhage risk – a near-zero net benefit that has driven the search for safer catheter-based alternatives. “Focus on clinical deterioration, not mortality” – Due to crossover design in contemporary PE RCTs, control-arm patients who decompensate are rescued with advanced therapies, biasing mortality toward the null. Clinical deterioration is the most informative endpoint to watch in HI-PEITHO, PRAGUE-26, and PEERLESS II. HI-PEITHO is the first large RCT to demonstrate that catheter-directed fibrinolysis plus anticoagulation significantly reduces the composite of PE-related death, cardiorespiratory decompensation, or PE recurrence versus anticoagulation alone (RR 0.39; 95% CI 0.20–0.77; P=0.005), with no intracranial hemorrhage in either arm. The four major upcoming/recently reported PE RCTs (HI-PEITHO, PRAGUE-26, PEERLESS II, PE-TRACT) enroll progressively different risk populations – from the most enriched (HI-PEITHO) to the most permissive (PE-TRACT, which includes intermediate-low risk patients) – enabling a nuanced understanding of which patients benefit most from intervention. PE device clearance follows a fundamentally different FDA pathway than structural heart devices (single-arm safety/efficacy studies vs. mandated RCTs), yet market forces and clinical need have ultimately driven industry and government to sponsor large-scale RCTs – a lesson in how evidence development can evolve organically alongside regulatory frameworks. Notes: Notes drafted by Dr. Shiavax Rao. Question #1: What is the current evidence behind advanced PE therapies? Systemic thrombolysis: Sixteen RCTs over 40 years (1972–2014) enrolling nearly 2,000 patients have studied systemic thrombolysis in intermediate-risk PE. The landmark PEITHO trial (n=1,006) showed that tenecteplase reduced the composite of death or hemodynamic collapse (2.6% vs. 5.6%; P=0.015), driven primarily by reduced hemodynamic decompensation (1.6% vs. 5.0%; P=0.002). However, this came at the cost of increased major bleeding (6.3% vs. 1.5%; P

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning discusses the Centers for Medicare & Medicaid Services proposed decision memo regarding the national coverage analysis for transcatheter aortic valve replacement (TAVR). Chapters 00:00 Intro 01:17 TAVR National Coverage 06:05 JANS 1, EPOCH CardioLink-10 Trial 10:20 JANS 2, Dacron Ross Autograft Analysis 12:23 JANS 3, Mech vs Biopros Valve Outcomes 15:53 Video 1, Ross Procedure I/E Reduction 19:18 Video 2, Hemi-Commando Procedure 22:14 Video 3, Left VATS Enucleation Leiomyoma 24:15 Dr. Meguid, Intraop Molecular Imaging 35:52 Closing He outlines crucial deadlines, actionable steps for surgeons, the importance of submitting public comments, and the necessity of data collection. Additionally, he spoke with Dr. Robert Meguid, Professor of Surgery at the University of Colorado Anschutz Medical Campus, Aurora, CO, USA, about intraoperative molecular imaging. They explore how this technology identifies small nodules, the functionality and use cases of the specialized camera, the associated learning curve, and other available systems. The conversation also touches on robotics, lymph node staging, and cost. Furthermore, Dr. Meguid shares insights on his frequency of use of this technique. Joel also highlights recent JANS articles on a systematic review and meta-analysis on how complete Dacron reinforcement of Ross autograft does not increase neo-aortic valve regurgitation, a randomized trial on superficial parasternal intercostal plane block with ropivacaine vs placebo for opioid exposure after cardiac surgery, and outcomes after conversion from mechanical to bioprosthetic valves for anticoagulation-related complications. In addition, Joel explores the Ross procedure with internal and external reduction annuloplasty using autologous tissue rings, hemi-commando procedure for bioprosthetic aortic valve endocarditis, and left-sided uniportal VATS enucleation of a large esophageal leiomyoma. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned Complete Dacron Reinforcement of Ross Autograft Does Not Increase Neo-Aortic Valve Regurgitation: A Systematic Review and Meta-Analysis Superficial Parasternal Intercostal Plane Block With Ropivacaine Versus Placebo for Opioid Exposure After Cardiac Surgery (EPOCH CardioLink-10): A Multicentre, Double-Blind, Randomised Trial Outcomes After Conversion From Mechanical to Bioprosthetic Valves for Anticoagulation-Related Complications CTSNet Content Mentioned Ross Procedure With Internal and External Reduction Annuloplasty Using Autologous Tissue Rings Hemi-Commando Procedure for Bioprosthetic Aortic Valve Endocarditis Left-Sided Uniportal VATS Enucleation of a Large Esophageal Leiomyoma Other Items Mentioned Centers for Medicare & Medicaid Services Database—TAVR Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning discusses the transcatheter aortic valve replacement (TAVR) heart team potentially losing a member. He explores the current composition of the TAVR heart team, proposed changes, the thoughts of cardiothoracic societies, and future actions regarding this issue. Chapters  00:00 Intro  01:53 TAVR Heart Team  07:48 JANS 1, Base Editing of PCSK9  09:47 JANS 2, High Volume Valve Sparing ARR  12:03 JANS 3, Western Rheumatic Heart Disease  14:05 JANS 4, Non-Intubated Uniportal VATS SL  15:38 Video 1, Miami Method-Bentall  17:02 Video 2, ALCAPA Repair  18:29 Video 3, Robotic Cardiac Podcast  22:17 Dr. Sundt, Mantle Radiation Patients  31:17 Upcoming Events  Additionally, he spoke with Dr. Thoralf Sundt, Chief of the Division of Cardiac Surgery and Director of the Corrigan Minehan Heart Center at Massachusetts General Hospital, Boston, MA, USA, about patients who have undergone mantle radiation. They discuss the challenges these patients face postoperatively, including the mortality rate associated with reoperations. The conversation also highlights the significance of employing a heart team approach for these patients, emphasizing the importance of preoperative planning and the application of TAVR, which is potentially suitable for these patients. Furthermore, they touch upon topics such as mechanical valves, porcelain aorta, and the importance of conducting careful operations on these patients. Joel also highlights recent JANS articles on in vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia, defining high-volume centers using prospective data for valve-sparing aortic root replacement, insights from the Netherlands Heart Registration on surgical care for rheumatic heart disease patients, and a cohort study on surgical techniques and outcome analysis of non-intubated uniportal VATS sleeve lobectomy. In addition, Joel explores a step-by-step technique for a minimally invasive Bentall procedure via right axillary access, the repair of an anomalous left coronary artery from the pulmonary artery via direct coronary transfer, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Husam Balkhy about multi-spectrum robotic cardiac surgery. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned In Vivo Base Editing of PCSK9 With VERVE-102 for Hypercholesterolemia Valve-Sparing Aortic Root Replacement: Defining High-Volume Centres Using Prospective Data Surgical Care for Rheumatic Heart Disease Patients: Insights From the Netherlands Heart Registration Surgical Techniques and Outcome Analysis of Non-Intubated Uniportal VATS Sleeve Lobectomy: A Cohort Study CTSNet Content Mentioned Minimally Invasive Bentall Procedure via Right Axillary Access: A Step-by-Step Technique Repair of Anomalous Left Coronary Artery From the Pulmonary Artery via Direct Coronary Transfer The Atrium: Multi-Spectrum Robotic Cardiac Surgery Other Items Mentioned Cardiac Reoperations in Patients With Prior Thoracic Radiation: A Single-Center Analysis of Outcomes and Key Lessons CTSNet Innovation Video Competition Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Send us Fan MailHeart valve disease affects millions of people, yet treatment isn't one-size-fits-all. When surgery becomes necessary, doctors may recommend repairing the existing valve or replacing it entirely. In today's episode, Dr. Richard Kettelkamp, medical director for St. Luke's Heart Care Services, returns to the podcast to break down each option, discuss how doctors decide which approach is best, and what it means for patients and their quality of life. To learn more, visit unitypoint.org/cr-heart. If you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Isaac George, CTSNet Board Member and Co-Director of the Structural Heart and Valve Center, Surgical Director of Structural Heart Disease, and Co-Director of the Mitral and Tricuspid Center at Columbia University Medical Center/NewYork-Presbyterian, NY, USA, about the lifetime management of aortic valve disease. Chapters 00:00 Intro 02:11 AATS-CTSN Randomized Trials 04:37 JANS 1, Consensus Statement ALAD 10:28 JANS 2, Lung Re-Transplantation Outcomes 12:19 JANS 3, Aortic Homografts, EURECAH 15:15 JANS 4, Lobectomy Cost Analysis 18:10 Video 1, Anomalous L Coronary Artery 19:38 Video 2, Pulm Valve Replacement Reop 21:38 Video 3, Giant Pulm Artery Aneurysm 23:28 Dr. George Discussion 33:18 Upcoming Events 34:05 Closing They explored the expansion of transcatheter aortic valve replacement (TAVR), emphasizing the crucial role of the heart valve team in this process. The discussion highlighted the necessity for surgeons to be actively involved in the decision-making process surrounding TAVR, particularly in the early stages. They also addressed the importance of lifetime management of the valve, selecting the appropriate valve, and valve durability. Additionally, they discussed the significance of providing patients with multiple surgical options, the Ross procedure, mechanical valves, and explored which procedures patients are choosing. Joel also highlights recent JANS articles on the ISHLT consensus statement on acute lung allograft dysfunction, aortic homografts for native and prosthetic aortic valve and root endocarditis, how outcomes after lung re-transplantation for restrictive allograft syndrome have not improved over two decades, and the financial burden of postoperative adverse events following lobectomy. In addition, Joel explores the surgical repair of an anomalous left coronary artery from the right pulmonary artery, minimally invasive pulmonary valve replacement in reoperative settings, and surgical management of giant pulmonary artery aneurysm using a T-shaped graft-valve strategy. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned ISHLT Consensus Statement on Acute Lung Allograft Dysfunction (ALAD): Definition, Etiology, Diagnostic and Therapeutic Approaches, and Research Priorities Aortic Homografts for Native and Prosthetic Aortic Valve and Root Endocarditis: Results From the EUropean REgistry of Cryopreserved Aortic Homografts EURECAH Outcomes After Lung Re-Transplantation for Restrictive Allograft Syndrome Have Not Improved Over Two Decades Financial Burden of Postoperative Adverse Events Following Lobectomy: Cost Analysis From 10 High-Volume Canadian Hospitals CTSNet Content Mentioned Surgical Repair of an Anomalous Left Coronary Artery From the Right Pulmonary Artery Minimally Invasive Pulmonary Valve Replacement in Reoperative Settings Surgical Management of Giant Pulmonary Artery Aneurysm Using a T-Shaped Graft-Valve Strategy Other Items Mentioned CTSNet Innovation Video Competition Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Commentary by Dr. Jinho Lee.

Commentary by Dr. Jian'an Wang.

Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, and a CMS proposal to expand TAVR coverage are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback ICD Trends and Outcomes: 15-Year Analysis https://doi.org/10.1093/europace/euag110 MADIT-RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 II More Long Term Data on TAVR vs SAVR PARTNER 2 Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.03.169 10-Year Outcomes of SAPIEN 3 TAVR or SAVR in Intermediate-Risk Patients https://doi.org/10.1016/j.jacc.2026.03.170 TAVR at a Decade: Editorial https://doi.org/10.1016/j.jacc.2026.04.042 EVOLUT Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 Updated 5-year Outcomes of TAVR vs SAVR in AS https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 NOTION Trial https://doi.org/10.1093/eurheartj/ehae043 PARTNER 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 NOTION 2 Trial https://academic.oup.com/eurheartj/article/45/37/3804/7673297 TAVR vs SAVR Editorial : https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag407/8708044 III The PREVUE-VALVE Study PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 IV CMS has Proposed New Coverage for TAVR CMS Proposal Document https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=321 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Drs. Dasgupta and Sarswat review how ATTR cardiomyopathy remains under-recognized despite its prevalence in older patients with heart failure, emphasizing clinical red flags across cardiac and systemic manifestations. They outline a practical diagnostic pathway that prioritizes early identification using light-chain evaluation, bone scintigraphy, and genetic testing to distinguish transthyretin subtypes and initiate timely, disease-modifying therapy.

In this episode, Curtiss T. Stinis, MD, FACC, FSCAI, Clinical Professor of Medicine, Director of Peripheral Interventions, Interventional Cardiology, Scripps Clinic, joins the Becker's Healthcare Podcast to discuss the latest TAVR durability data, key differences between leading valve platforms, and what health system leaders need to understand about lifetime valve management.This episode is sponsored by Edwards Lifesciences.

LBCT: Real-World Reintervention Rate Among TAVR Low-Risk Medicare Patients

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Gilbert Tang, Editor-in-Chief of Journal of the American College of Cardiology (JACC): Case Reports, professor in the Department of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, surgical director of the Structural Heart Program at Mount Sinai Health System, and the director of Structural Heart Education at the Mount Sinai Fuster Heart Hospital in New York, NY, USA. They were joined by Drs. Mateo Marin-Cuartas, associate editor of JACC: Case Reports, CTSNet JANS Editor, and cardiac surgeon at Leipzig Heart Center, Germany, and Tsuyoshi Kaneko, Chair of American College of Cardiology (ACC) Cardiac Surgery Member Section and Chief of Cardiac Surgery at Washington University in St. Louis, MO, USA, to discuss JACC: Case Reports. Chapters 00:00 Intro 01:45 Instructional Video Competition 05:30 JANS 1, Lung Cancer Metastasis 09:08 JANS 2, Uncorrected Pectus 11:29 JANS 3, Ambulatory VV Life Support 13:38 JANS 4, EuroSCORE II 14:28 Video 1, TAVR Removal Double Patch 16:09 Video 2, ROK Procedure AF 17:46 Video 3, RATS Lobectomy 19:11 JACC Case Reports 35:28 Upcoming Events 36:03 Career Center They discussed the mission of the journal and the types of submissions it receives. They also covered the types of cases accepted and the various categories within the journal has, such as the "How We Did It" section. Additionally, they talked about the upcoming partnership between JACC: Case Reports and the ACC, as well as past collaborations that JACC has undertaken. Dr. Marin-Cuartas shared insights about his role as an associate editor and highlighted the most interesting case he has encountered in JACC: Case Reports. Furthermore, Dr. Kaneko discussed being the Chair of the ACC Cardiac Surgery Member Section. Joel also highlights recent JANS articles on the evolutionary characterization of lung cancer metastasis, the impact of severe uncorrected pectus excavatum on outcomes after aortic surgery in Marfan syndrome, determining an optimal central cannulation strategy for ambulatory veno-venous extracorporeal life support, and refitting EuroSCORE II for 120-day mortality after coronary artery bypass grafting using nationwide registry data. In addition, Joel explores complex imaging TAVR removal double patch double valve, RATS extended left upper lobectomy with intrapericardial vascular control and bronchoplasty, and ROK procedure for the treatment of atrial fibrillation. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned Evolutionary Characterization of Lung Cancer Metastasis Impact of Severe Uncorrected Pectus Excavatum on Outcomes After Aortic Surgery in Marfan Syndrome Determining an Optimal Central Cannulation Strategy for Ambulatory Veno-Venous Extracorporeal Life Support Refitting EuroSCORE II for 120-Day Mortality After Coronary Artery Bypass Grafting Using Nationwide Registry Data CTSNet Content Mentioned Complex Imaging TAVR Removal Double Patch Double Valve RATS Extended Left Upper Lobectomy With Intrapericardial Vascular Control and Bronchoplasty ROK Procedure for the Treatment of Atrial Fibrillation Other Items Mentioned JACC: Case Reports 2026 Instructional Video Competition Winners Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Another positive digoxin trial, another classic coronary physiology study from Imperial College London (ORBITA-FIRE), news in hypertrophic cardiomyopathy, and TAVR done in the wrong patients are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Digoxin in Rheumatic Heart Disease Dig-RHD Trial https://jamanetwork.com/journals/jama/fullarticle/2848973 Safety and Efficacy of Digoxin: Meta-Analysis https://www.bmj.com/content/351/bmj.h4451.long DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471 DIG Trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801 RADIANCE Trial https://www.nejm.org/doi/full/10.1056/NEJM199307013290101 II The Physiologic Threshold for Angina ORBITA-FIRE Trial https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.078738 III Prediction in Hypertrophic Cardiomyopathy Predictors of Long-Term Outcomes in HCM https://jamanetwork.com/journals/jama/fullarticle/2848800#250998713 IV TAVR Trends in Young Patients Temporal Trends in AVR for Aortic Stenosis in Patients < 65 https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016826 Wall Street Journal article https://www.wsj.com/health/healthcare/heart-valve-tavr-surgery-aorta-1e0eda70 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to announce that the company has reached a major milestone by enrolling and treating the first patients in the United States for its DurAVR Transcatheter Heart Valve global pivotal trial. These landmark procedures were conducted at the Montefiore Medical Center in New York and were specifically performed for patients diagnosed with severe calcific aortic stenosis. Paterson noted during the announcement that conducting these initial U.S. cases within the global PARADIGM Trial represents a significant achievement for the investigators involved and offers valuable early procedural experience with the DurAVR THV System. The PARADIGM Trial is uniquely designed to address clinically meaningful questions that extend beyond standard safety metrics and basic hemodynamics. One of its core research objectives is to evaluate the specific impact of valve flow patterns on left ventricular recovery. According to the company, initiating this enrollment phase is a critical step in generating the high-quality evidence required to shape future standards of patient care. As a prospective randomized controlled trial, the study is set to evaluate the safety and clinical effectiveness of the DurAVR THV in direct comparison to various commercially available transcatheter aortic valve replacements currently on the market. The trial is expected to enroll approximately 1,000 patients into its 'All Comers Randomized Cohort'. Through a 1:1 randomization protocol, participants will be assigned to receive either the DurAVR THV or a standard TAVR using currently approved, commercially available heart valves. Ultimately, the trial investigators will assess non-inferiority based on a primary composite endpoint that tracks all-cause mortality, all instances of stroke, and cardiovascular-related hospitalizations exactly one year after the procedure has been completed. #proactiveinvestors #anteristechnologiesglobalcorp #asx #avr #nasdaq #avr #DurAVR #TAVR #HeartValve #ClinicalTrials #Cardiology #AorticStenosis #MedicalDevice #HealthcareInnovation #PARADIGMTrial #Biotech #MedTech #PatientCare #FDA #Cardiovascular

Contributor: Taylor Lynch, MD Educational Pearls:    Conduction abnormalities are a common and clinically significant complication in patients who undergo transcatheter aortic valve replacement (TAVR)   Clinical Features The most common abnormalities include high grade AV block and new onset LBBB  Due to the close proximity of the aortic annulus to the AV node and His-Purkinje system More common in males, the elderly, and those with pre-existing conduction disease (RBBB or LBBB) Sinus pauses and sinus arrest are a rare post-TAVR rhythm disturbances Temporary failure of sinus node firing with absent P waves, followed by return of sinus rhythm Sinus Pauses: Typically last < 3 seconds Sinus Arrest: Typically last > 3 seconds Not due to direct mechanical injury from the valve, but may occur in patients as a result of pre-existing disease or other external factors: Medications Beta blockers, calcium channel blockers, digoxin Pre-existing damage to the SA node Fibrosis from a previous MI   Treatment If the patient is asymptomatic, provide ongoing surveillance If the patient is symptomatic, treatment should be aimed at the underlying cause: For medication-induced abnormalities, stop the offending medication For acute, unstable bradycardia: Medications: Atropine, Dopamine Infusion, Epinephrine Infusion If cardiology is not immediately available, initiate transcutaneous pacing or insert a temporary transvenous pacemaker Definitive treatment: Pacemaker ~10–15% of patients may develop a bradyarrhythmia post TAVR, with ~8-15% later requiring a pacemaker   Due to the risk of conduction abnormalities post TAVR, many patients are discharged with ambulatory rhythm monitoring such as a ZioPatch or Holter monitor, and may present to the emergency department for evaluation of rhythm disturbances.   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf  

LBCT: Real-World Reintervention Rate Among TAVR Low-Risk Medicare Patients

King and I | S6 E8 | Long-Term Follow-Up after TAVR and What Signal Should be Urgently Reported to the Public

Welcome back to the Brown Surgery Podcast. In this episode, we catch up with Dr. Laura Scrimgeour, a familiar voice to our longtime listeners. Since her last appearance as a chief resident in 2021, Dr. Scrimgeour has completed an extensive journey through cardiothoracic training and now returns to Brown as an attending surgeon.Together, we dive deep into what it takes to thrive in the field of Cardiothoracic (CT) Surgery in 2026. Whether you are a medical student weighing your residency options or a general surgery resident considering a fellowship, this conversation offers a roadmap for navigating the complexities of the specialty.In this episode, we discuss:The Path to CT Surgery: Deciding between traditional and integrated training pathways and the value of a strong academic foundation.The Role of Research: Why "checking the box" isn't enough, and how research years build critical mentorship and data-analysis skills.Fellowship Selection: What to look for in a program, from operative volume and case diversity to the importance of autonomy and mentorship.The Future of the Field: The current state of robotics in cardiac surgery and the rising importance of advanced fellowships in areas like TAVR and aortic surgery.Breaking Misconceptions: A candid look at the life of a modern CT surgeon, the growing diversity in the OR, and how team-based structures are improving work-life balance.Life Outside the Hospital: How Dr. Scrimgeour balances a demanding surgical schedule with her passion for the outdoors and skiing.Instagram: @dr.laura.scrimgeourX: @LScrimgeourMD

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. John Forrest, a cardiologist and Director of both Interventional Cardiology and the Structural Heart Disease Program at Yale Medicine, New Haven, CT, USA, about a paper he authored titled “Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis,” published by the Journal of the American College of Cardiology. Chapters 00:00 Intro  02:38 TAVR vs SAVR Context  03:54 CDC WONDER Data, TAVR SAVR  05:37 JANS 1, TAVR vs SAVR 5-Year Outcomes  07:31 JANS 2, Temporary MCS Devices Landscape  09:17 JANS 3, Pulm Resection Post-CABG  10:23 JANS 4, PRE-HIIT Randomized Trial  12:36 Career Center  13:10 Video 1, Redo MVR After VIV TAVR  15:37 Video 2, Repair After Acute Intramural Hematoma  18:01 Video 3, Acute Severe MR Repair  19:36 Dr. Forrest, 6-Year TAVR vs SAVR  44:49 Upcoming Events  45:33 The Lifeline Podcast  They explored other randomized trials involving high-risk and intermediate-risk patients with aortic stenosis and examined the specific goals of this low-risk trial. The discussion then delved into the trial's results, highlighting that there was no significant difference in the composite endpoint of all-cause mortality or disabling stroke. However, a noteworthy finding was that the transcatheter aortic valve replacement (TAVR) arm experienced a higher reintervention rate compared to surgery, primarily due to an increased incidence of aortic regurgitation. They also addressed factors such as valve dilation, stents, and various reasons for surgical valve failure. Additionally, they examined the similarities between this trial and other partner trials and the future for low-risk patients with aortic stenosis.   Joel also highlights recent JANS articles on the updated five-year outcomes of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low- to intermediate-surgical risk, a United States nationwide analysis on the changing landscape of temporary mechanical circulatory support devices in the new heart allocation system, pulmonary resection post-coronary artery bypass grafting, and a randomized controlled trial on the preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or esophagus (PRE-HIIT).  In addition, Joel explores redo mitral valve replacement after previous valve-in-valve mitral TAVR, aortic repair after acute intramural hematoma, and repair of acute severe mitral regurgitation due to iatrogenic papillary muscle rupture. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Updated 5-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low- to Intermediate-Surgical Risk  2.) The Changing Landscape of Temporary Mechanical Circulatory Support Devices in the New Heart Allocation System—A United States Nationwide Analysis  3.) Pulmonary Resection Post-Coronary Artery Bypass Grafting: Feasible, but Right-Sided Procedures Demand Caution  4.) Preoperative Exercise to Improve Fitness in Patients Undergoing Complex Surgery for Cancer of the Lung or Esophagus (PRE-HIIT): A Randomized Controlled Trial  CTSNet Content Mentioned  1.) Redo Mitral Valve Replacement After Previous Valve-in-Valve Mitral TAVR  2.) Aortic Repair After Acute Intramural Hematoma   3.) Repair of Acute Severe Mitral Regurgitation Due to Iatrogenic Papillary Muscle Rupture  Other Items Mentioned  1.) Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis  2.) The Lifeline: End-Tidal Carbon Dioxide Monitoring in Cardiac Surgical Emergencies  3.) Instructional Video Competition     4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Drs. Mateo Marin-Cuartas, CTSNet JANS Editor and cardiac surgeon at the University Department of Cardiac Surgery at Leipzig Heart Centre University Hospital in Leipzig, SN, Germany; and Samuel Heuts, a cardiothoracic surgeon in the Department of Cardiothoracic Surgery at Maastricht University Medical Center in Maastricht, LI, about a paper they authored titled “Updated 5-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low- to Intermediate-Surgical Risk,” published in Heart, a journal produced by the British Medical Journal. Chapters 00:00 Intro 01:51 JANS 1, 6-Year Outcomes TAVR vs SAVR 06:45 JANS 2, Evolut THV Postdilation 09:22 Video 2, TAVI in SAVR Explantation 11:10 JANS 3, High Risk Increasing Adoption of DCD 13:17 JANS 4, Lobar Quantitation for Assessment 15:16 Video 1, Narayana Robotic AVR 17:23 Video 3, Extended Resections Podcast 18:30 Dr. Marin-Cuartas & Heuts, TAVR vs SAVR 36:42 Upcoming Events 37:32 Instructional Video Competition 38:55 Career Center They discussed the motivations behind the creation of this paper and provided insights into its Bayesian hierarchical design. Key findings included the five-year all-cause mortality rates and the risk of stroke associated with the procedures. They also referenced other studies with similar findings, such as a recently published paper from the Journal of the American College of Cardiology on the “Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.” Finally, they explored the future of transcatheter aortic valve implantation and surgical aortic valve replacement.   Joel also highlights recent JANS articles on the six-year outcomes after transcatheter vs surgical aortic valve replacement in low-risk patients with aortic stenosis, postdilation of Evolut transcatheter heart valves, insights into current practices in the United States regarding increasing adoption of donation after circulatory death in high-risk heart transplant recipients, and the value of V/Q SPECT/CT lobar quantitation for pre-treatment assessment of lung malignancy.  In addition, Joel explores robotic-assisted aortic valve replacement, TAVI in SAVR explantation, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Maninder Kalkat about extended resections. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis  2.) Postdilation of Evolut Transcatheter Heart Valves: Insights From Bench Testing  3.) Increasing Adoption of Donation After Circulatory Death in High Risk Heart Transplant Recipients: Insights Into Current Practices in the United States  4.) The Value of V/Q SPECT/CT Lobar Quantitation for Pre-Treatment Assessment of Lung Malignancy  CTSNet Content Mentioned  1.) Robotic-Assisted Aortic Valve Replacement   2.) TAVI in SAVR Explantation: A Two-Step Technique for Successful Removal   3.) The Atrium: Extended Resections   Other Items Mentioned  1.) Updated 5-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low- to Intermediate-Surgical Risk  2.) The Lifeline  3.) Instructional Video Competition     4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Commentary by Dr.  Jian'an Wang

Commentary by Dr. Matteo Sturla

Deacon Al shares personal stories—from backyard wildlife and a fussy nightstand build to a new bicuspid aortic valve diagnosis and possible TAVR procedure—while reflecting on trust in God during illness. He also highlights the surge of RCIA converts, explains the Second Sunday of Lent readings (Abraham, Paul to Timothy, the Transfiguration), and invites listeners to encounter Christ through the sacraments, prayer, and Lenten practices. Email your questions to Deacon AL:    goodnews@catholicspiritradio.org  

This week, we cover a range of topics: urinary vs cervical HPV collection, the benefits and harms of Tramadol, whether patients need anticoagulation after successful ablation for afib, and the ongoing value of COVID vaccines in the omicron era. Plus a quiz: is TAVR now indicated for everyone with severe aortic stenosis? Stay tuned!

Radikal tavır 00:08 – Mindfulness ve Terapinin Birleşme Fikri 01:13 – Sorunları Çözmek Yerine Alan Açmak 03:27 – Ebeveyn–Çocuk İlişkisinde Alan Tutmak 05:29 – Kişisel Deneyim: Futbol Kampı ve Yargısız Dinlemek 09:42 – Alan Açmanın Gücü ve Küçük Farkların Etkisi 10:23 – Eğitmenin Tavrı ve Devamlılık İlkesi 12:29 – Kişisel Pratik Yapmadan Öğretilemez 14:25 – Deneyim ve Teknik: Dağ Tırmanışı Benzetmesi 14:31 – Katılımcıya ve Öğrenciye Saygı Zeynep Aksoy bu bölümde mindfulness ve meditasyonun terapiyle nasıl birleştiğini, bu fikrin önce teorik olarak ortaya çıktığını ve sonradan içinin doldurulduğunu anlatıyor. MBSR eğitimlerinde sorunları çözmek yerine zor duygu ve düşüncelere alan açma yaklaşımının terapistler için ne kadar radikal olduğunu paylaşıyor. Eğitmenin kendi pratiğinin önemini, yargısız ve davetkâr bir tavrın hem terapide hem ebeveynlikte nasıl dönüştürücü olabileceğini kişisel bir deneyim üzerinden örneklendiriyor. Mindfulness'ın teknikten öte bir duruş olduğunu ve öğretmenin bunu kendi pratiğiyle taşıması gerektiğini vurguluyor. Zeynep Aksoy, saygın bir yoga eğitmeni ve Reset platformunun kurucusudur. Web sitesi üzerinden canlı ve kayıttan izlenebilen dersler, üyelik programları ve profesyonel eğitimler sunmaktadır. Online Stüdyo üyeliği ile günlük çevrim içi derslere, geniş bir arşive ve topluluk desteğine erişim imkânı sağlar. Ayrıca Zeynep, katılımcıların hareket, anatomi ve farkındalık konularında bilgilerini derinleştirmelerine yardımcı olmak için yenilikçi Fasyal Yoga Uzmanlık Programı'nı yürütmektedir. Daha fazla bilgi almak ve sertifikalı eğitimlere katılmak için: www.zeynepaksoyreset.com

A special, interactive Doc Talk event recorded live in front of an audience at The Monument in Rapid City in honor of Valve Disease Awareness Day. Joseph Tuma, M.D., FACC, FSCAI, Interventional Cardiologist at Heart and Vascular Institute leads a discussion in which guests and audience members alike share stories of their Transcatheter Aortic Valve Replacement (TAVR) procedures.Don't miss out on one of our most unique and informative Doc Talks yet. Hosted on Acast. See acast.com/privacy for more information.

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813 Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034 TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031 UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251 Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA II DNR in the Hospital Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203 GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193 TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 IV Good news in HFpEF Evidence ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016 V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Dr. Peter Fail and Dr. Shane Prejean break down structural heart and valve disease - including what it is, common warning signs, and advanced treatment options that can improve quality of life for patients, such as Transcatheter Aortic Valve Replacement (TAVR), as well as their recent milestone of completing their 1,000th TAVR.Visit www.cardio.com for more information or to schedule an appointment with one of our providers.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Louise Kenny, a consultant pediatric and adult congenital cardiothoracic and transplant surgeon at Freeman Hospital in Newcastle upon Tyne, England, about congenital heart transplants. Chapters 00:00 Intro 02:24 JANS 1, VECTOR Procedure 07:38 JANS 2, Combined Inflation & Cooling 08:26 JANS 3, Caring for VIP Patients 11:43 JANS 4, Country Wealth & Min Inv Correlation 12:57 Career Center 13:37 Video 1, Debranching AAV Step-by-Step 15:14 Video 2, Abramson Technique 16:59 Video 3, Min Inv Cardiac w Dr. Chitwood 18:54 Dr. Kenny, DCD-HOPE Congenital Transplant 31:58 CKD & CSA-AKI Podcast Episode 34:12 Upcoming Events 35:13 Closing They discussed the complexities surrounding congenital heart transplants, donation after brain death (DBD), and donation after circulatory death (DCD). They also explored the benefits of hypothermic oxygenated perfusion (HOPE) for children, particularly in DCD pediatrics patients, and highlighted the first case where this model was used. Additionally, they examined the future of HOPE and its potential for more complex procedures. Moreover, they discussed implanting ventricular assist devices (VAD) in children, along with what other countries are doing regarding congenital heart transplants, including ongoing studies in this field.    Joel also highlights recent JANS articles on the first human VECTOR procedure for percutaneous aorto-coronary bypass graft to prevent coronary obstruction following TAVR, combined inflation and cooling method improves lung function in uncontrolled donation after circulatory death, caring for VIP patients in cardiothoracic surgery, and the national wealth and the global spread of minimally invasive thoracic surgery.  In addition, Joel explores a step-by-step guide for debranching of aortic arch vessels through a cervical approach for aortic arch aneurysm, a master class with Horacio Abramson on the Abramson technique, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Randolph Chitwood about the future of minimally invasive cardiac surgery. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Percutaneous Aorto-Coronary Bypass Graft to Prevent Coronary Obstruction Following TAVR: First Human VECTOR Procedure  2.) Combined Inflation and Cooling Method Improves Lung Function in Uncontrolled Donation After Circulatory Death  3.) Caring for VIP Patients in Cardiothoracic Surgery: Navigating Bias, Pressure, and Protocol  4.) National Wealth and the Global Spread of Minimally Invasive Thoracic Surgery: Insights From the European Society of Thoracic Surgeons Database  CTSNet Content Mentioned  1.) Debranching of Aortic Arch Vessels Through a Cervical Approach for Aortic Arch Aneurysm: A Step-by-Step Guide  2.) Master Class: The Abramson Technique With Horacio Abramson and Joel Dunning  3.) The Atrium: The Future of Minimally Invasive Cardiac Surgery  Other Items Mentioned  1.) HOPE for Children: Successful Pediatric DCD Heart Transplantation Using Hypothermic Oxygenated Perfusion  2.) Instructional Video Competition   3.) Career Center   4.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Send us a textSt. Luke's introduced TAVR – catheter-based replacement of the aortic valve – to Cedar Rapids, performing the area's first procedure in 2016. Since then, the heart team has performed nearly 800 TAVRs. Joining the podcast to talk about the procedure are Dr. Richard Kettelkamp and Katie Maybanks, ACNP, from St. Luke's structural cardiology team. To learn more about heart care services at St. Luke's, Cedar Rapids' Heart Hospital, visit unitypoint.org/cr-heart. Do you have a question about a trending medical topic? Ask Dr. Arnold! Submit your question and it may be answered by Dr. Arnold on the podcast! Submit your questions at: https://www.unitypoint.org/cedarrapids/submit-a-question-for-the-mailbag.aspxIf you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.

Listener feedback, the value of procedural volume for TAVR and MTEER, ventricular arrhythmia in older athletes, and the Goldilocks time horizon for predicting and modifying CV risk are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Procedural Volume and Outcomes for TAVI and M-TEER Operator Procedural Volumes and Outcomes for TAVR and MTEER https://jamanetwork.com/journals/jamacardiology/fullarticle/2843740 II Ventricular Arrhythmia in Older Male Endurance Athletes Myocardial Fibrosis May Raise Arrhythmia Risk in Older Male Endurance Athletes https://www.medscape.com/viewarticle/myocardial-fibrosis-may-raise-arrhythmia-risk-older-male-2026a10001y0 Timing and Relationship of VA With Exercise Patterns in Older Male Endurance Athletes https://doi.org/10.1093/eurjpc/zwag021 III Predicting Cardiac Risk and Statin Use 30-Year ASCVD Risk Among US Adults Aged 30-59 https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012348 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251386377

On this episode of the Donut of Destiny, hosts Sotirios Evangelou, MD, FSCCT and Nisha Hosadurg , MBBS speak with guest Alan Vainrib, MD on how computational fluid dynamics (CFD) is emerging as a powerful research tool for understanding blood-flow behavior in structural heart disease. Using CT/MRI-based models, CFD can simulate pressures, velocities, shear stress and even post-procedure hemodynamics — offering new possibilities for evaluating aortic stenosis, planning TAVR and guiding mitral, tricuspid and LAAO interventions.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Randas Batista, cardiac surgeon and founder of Vilela Batista Heart Foundation, about the surgical treatment of Eisenmenger syndrome. Chapters 00:00 Intro 02:51 JANS 1, DAMSUN-HF Study 05:41 JANS 2, TAVR vs SAVR Guidelines 07:45 JANS 3, Myocardial Infarction After CABG 10:31 JANS 4, VAD Bridge-to-Transplant 12:27 New Recruitment Guide 13:54 Video 1, Anomalous Right Coronary Artery 15:27 Video 2, Beating Heart Transplant OCS 17:51 Video 3, Aortic Dissection Podcast w Marc Moon 19:26 Randas Batista Interview 37:38 Upcoming Events They explored what Eisenmenger syndrome is and outlined the most common causes of the condition. They also delved into the history of this syndrome, highlighting the significant contributions of Viktor Eisenmenger and Paul H. Wood. Furthermore, they discussed the impact of this syndrome on lung function and extracting oxygen within the pulmonary artery. Dr. Batista shared valuable technical tips for performing the surgical procedure as well as solutions for managing this syndrome.   Joel also highlights recent JANS articles on the DAMSUN-HF study on AI-enabled digital auscultation for detecting heart failure with reduced ejection fraction in Sub-Saharan Africa, transcatheter or surgical aortic-valve replacement in low-risk patients at seven years, current clinical practices and future perspectives on periprocedural myocardial infarction after coronary artery bypass grafting, and an analysis of UNOS.  In addition, Joel explores anomalous right coronary artery, beating heart transplantation using the Organ Care "Heart-in-a-Box" System (OCS), and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Marc Moon about aortic dissection. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) AI-Enabled Digital Auscultation for Detecting Heart Failure With Reduced Ejection Fraction in Sub-Saharan Africa: The DAMSUN-HF Study  2.) Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years  3.) Periprocedural Myocardial Infarction After Coronary Artery Bypass Grafting: Current Clinical Practices and Future Perspectives  4.) Analysis of UNOS: Ventricular Assist Device as Bridge-to-Transplant in Paediatric Patients With Congenital Heart Disease  CTSNet Content Mentioned  1.) Anomalous Right Coronary Artery  2.) Beating Heart Transplantation Using the Organ Care "Heart-in-a-Box" System (OCS)  3.) The Atrium: Aortic Dissection  Other Items Mentioned  1.) The Cardiac Recovery Room  2.) Resident Video Competition  3.) 2025 CTSNet Recruitment Guide   4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251336314

Aaysha Cader, MD MSc, social media editor for JACC: Cardiovascular interventions and Josep Rodés-Cabau, MD, PhD discuss the Impact of Early Hemodynamic Valve Deterioration on Long-term Outcomes Following Transcatheter Aortic Valve Replacement, published in the October 27 issue of the journal.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Outcomes of Telemedicine TAVR Preoperative Evaluations.

Examining the claim that cabbage family vegetables are bad for the thyroid; Walmart announces sweeping move to reformulate its products without synthetic dyes, sketchy additives; Under Congressional questioning, Google admits to censoring contrary narratives on YouTube during Covid; Children garner psychological benefits from grandparent time; J&J fined nearly $1 billion in landmark talc baby powder lawsuit; Humans are among the few animals who can't make their own vitamin C—why that may be a good thing.

In the September 22 episode of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz explores the concept of "computable quality" in healthcare, advocating for real-time, data-driven improvement in clinical care. He reviews original research on pop-up cardiovascular screenings in pharmacies and sporting events, AI-driven echocardiographic automation, and anticoagulation in pulmonary arterial hypertension. The episode also features a three-part debate on transcatheter aortic valve replacement (TAVR) in low-risk patients, highlighting evolving evidence, clinical implications, and calls for guideline reassessment. Tune in for insights on innovation, equity, and the future of cardiovascular care.

In this episode of Medsider Radio, we sat down with Ahmed Elmouelhi, CEO of TRiCares.  TRiCares is developing Topaz, the first purpose-built transcatheter tricuspid valve replacement system — a technology designed specifically for the right side of the heart, where complex anatomy has made durable solutions elusive.Ahmed is a 20-year medtech veteran with leadership experience across electrophysiology, men's health, neuromodulation, and structural heart. Before joining TRiCares, he helped build multiple businesses at AtriCure and held key roles at Medtronic during the early days of TAVR. He also serves as Chairman of the American Heart Association in Minnesota.In this interview, Ahmed shares why adoption — not added complexity — is the ultimate measure of medtech innovation, how a small group of physician champions can accelerate clinical studies faster than internal resources alone, and why treating your board like collaborators in the “sandbox” leads to stronger partnerships and better outcomes.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Ahmed Elmouelhi.

JACC's July 29 issue explores why the ACURATE neo2 valve failed in its IDE trial, with a post-hoc analysis pointing to under-expansion in heavily calcified anatomies as a potential culprit. Though the valve is off the market, the findings raise critical questions about procedural success, device design, and future innovation in TAVR. Listen to our Deep Dive narrated by JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, as he goes into the science behind the peer review.

In this episode, Thomas Draper, Vice President of the Wellstar Center for Cardiovascular Care, joins Becker's to discuss how Transcatheter Aortic Valve Replacement (TAVR) has evolved into a cornerstone of structural heart programs. Tom shares how Wellstar built a multidisciplinary infrastructure around TAVR, leveraged data and AI to identify underserved patients, and embraced technology to maintain quality amid rapid growth. Tune in to hear how the expansion of TAVR indications, AI integration, and patient-centered strategy are shaping the future of cardiovascular care.This episode is sponsored by Edwards Lifesciences.

The FDA approval of TAVR for asymptomatic AS, digital health, subcutaneous vs transvenous ICD, and cryptogenic stroke in young adults are discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I  FDA announces approval for TAVR in pts with asymptomatic AS Edwards Press Release https://www.edwards.com/newsroom/news/2025-05-01-edwards-tavr-receives-fda-approval-for-patients-with-asymptomatic-severe-aortic-stenosis Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (EARLY TAVR) https://www.nejm.org/doi/full/10.1056/NEJMoa2405880 EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec Asymptomatic Aortic Stenosis: 'Time to Act' or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9 II PPG that Can Distinguish source of Tachycardia Machine-learning guided differentiation between photoplethysmography waveforms of supraventricular and ventricular origin https://doi.org/10.1016/j.cmpb.2025.108798 III PRAETORIAN -XL trial Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074576 Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN trial) https://www.nejm.org/doi/full/10.1056/NEJMoa1915932 Subcutaneous or Transvenous Defibrillator Therapy Letter to Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917 The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best https://www.medscape.com/viewarticle/937156 IV Stroke in Young People Burden of Modifiable Risk Factors in Young-Onset Cryptogenic Ischemic Stroke by High-Risk Patent Foramen Ovale https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049855 Migraine: A Key Factor in Young Adults With Unexplained Stroke https://www.medscape.com/viewarticle/migraine-key-factor-young-adults-unexplained-stroke-2025a10009jj U.S. stroke rate declining in adults 75 and older, yet rising in adults 49 and younger ASA statement https://newsroom.heart.org/news/u-s-stroke-rate-declining-in-adults-75-and-older-yet-rising-in-adults-49-and-younger Increasing stroke in the young https://doi.org/10.1016/j.ajpc.2020.100085 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I FAME 3 at Five Years Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4 Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299 Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057 II TAVR in Low-Risk Patients at 5 years 5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004 EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428 PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447 NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606 III The Matter of Pacemakers After TAVI JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028 Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals   IV Mavacamten Looks to Have Specific Indications EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050 BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/ FINAL THOUGHTS PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback on asymptomatic aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR), coronary artery calcium (CAC), and revascularization for patients with ischemic LV dysfunction are discussed by John Mandrola, MD, in today's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Aortic Valve Intervention for Asymptomatic AS Asymptomatic Aortic Stenosis: “Time to Act” or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9 EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec Reddy et al: https://doi.org/10.1016/j.jacc.2024.12.031 Wallach editorial https://doi.org/10.1016/j.jacc.2025.01.020 Guerrero https://www.tctmd.com/slide/tavr-young-patients-current-treatment-patterns-us II CAC - Coronary Artery Calcium Coronary Artery Calcium Testing—Too Early, Too Late, Too Often https://jamanetwork.com/journals/jamacardiology/fullarticle/2830950 CAUGHT-CAD https://jamanetwork.com/journals/jama/fullarticle/2831115 III CABG, PCI or Meds for Ischemic LV Dysfunction STICH https://www.nejm.org/doi/full/10.1056/NEJMoa1100356 STICHES https://www.nejm.org/doi/full/10.1056/NEJMoa1602001 REVIVED BCIS https://www.nejm.org/doi/full/10.1056/NEJMoa2206606 EHJ paper https://doi.org/10.1093/eurheartj/ehaf080 IV Preview https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net